Kyverna Therapeutics, Inc. Accounts Payable
Kyverna Therapeutics, Inc. (KYTX) had Accounts Payable of $2.93 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-11
- 2026-06-30: Accounts Payable, Current $2.93M.
- 2026-03-31: Accounts Payable, Current $11.60M.
- 2025-12-31: Accounts Payable, Current $5.31M.
- 2025-09-30: Accounts Payable, Current $3.02M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $2.93M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $11.60M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $5.31M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $3.02M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $9.92M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $8.47M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.62M 10-K · filed 2026-03-26 |
| 2024-09-30 | $9.93M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $4.86M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $7.45M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $4.36M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |